[Antiplatelet therapy in women: A gender-specificity?]
Women is a fragile and complex substet of patients, under-represented in clinical trials, but experiencing growing cardiovascular events, with higher mortality, delayed presentation, higher bleeding complications and undertreatment with antithrombotic therapies, compared to their male counterparts. Female gender has been associated with enhanced basal platelet reactivity, high residual on-treatment platelet reactivity and various responses to antiplatelet agents. Growing concern on gender-specificity has emerged, including potential difference in women compared with men on the benefits and risks of antiplatelet therapy in primary or secondary prevention and according the antiplatelet agent used. We provide here a review of available data on antiplatelet therapy in women.
Service de cardiologie, centre hospitalier d'Antibes-Juan-Les-Pins, 107, avenue de Nice, 06600 Antibes, France. Electronic address: annebellem1@hotmail.fr.
A
A
Bellemain-Appaix
D002986:Clinical Trials as Topic; D003328:Coronary Thrombosis / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008297:Male; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D012737:Sex Factors
D010975:Platelet Aggregation Inhibitors
Antiagrégant plaquettaire; Antiplatelet therapy; Aspirin; Aspirine; Clopidogrel; Femme; Gender; Genre; Grossesse; Prasugrel; Pregnancy; Ticagrelor; Women